BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
©The Author(s) 2026.
World J Gastrointest Endosc. Jan 16, 2026; 18(1): 113788
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.113788
Table 2 Primary and secondary study outcomes, n (%)
Outcomes
IND (n = 70)
LR (n = 70)
IND + LR (n = 70)
P value
PEP7 (10.00)12 (17.14)4 (5.71)1
Severe PEP1 (1.4)2 (2.8)2 (2.8)0.86
Pseudocyst1 (1.4)0 (0)0 (0)1.00
Pulmonary edema1 (1.4)1 (1.4)0 (0)0.92
Renal failure1 (1.4)1 (1.4)0 (0)0.93
Gastrointestinal bleeding1 (1.4)2 (2.8)0 (0)0.82
Anaphylaxis0 (0)0 (0)0 (0)0.98
Death2 (2.8)1 (1.4)1 (1.4)1.00
Readmission5 (7.14)7 (10)2 (2.8)1
Mean length of stay, days3.404.703.120.12


Write to the Help Desk